This white paper explores how Touchlight is redefining DNA payload design for next-generation gene editing and non-viral gene therapy. It introduces innovative circular DNA architectures such as mbDNA, sscDNA, hsscDNA,…
Read More
As the global demand for RNA-based therapeutics and vaccines accelerates, traditional plasmid DNA (pDNA) production methods often struggle to meet today’s biopharmaceutical landscape’s scalability and efficiency requirements. Touchlight’s z- dbDNA…
Read More
Touchlight today announced the expansion of its groundbreaking mbDNA™ platform with the introduction of three new circular DNA architectures: sscDNA, hsscDNA, and dscDNA.
Read More
This application note highlights the advantages of dbDNA™, a linear, enzymatically amplified DNA construct, as a cell-free alternative to plasmid DNA (pDNA) for lentiviral vector (LVV) production. Manufactured under GMP…
Read More
In this session, Elena Stoyanova, PhD (Touchlight) introduces mbDNA™ (Megabulb DNA), a novel single-stranded circular DNA template featuring a customizable stem region and fully user-defined sequence. Chesney Michels, PhD (ElevateBio)…
Read More
Touchlight announced today that its proprietary z- dbDNA™ technology is to be utilised as a critical starting material in the manufacture of a cutting-edge gene therapy for a US-based clinical…
Read More
Touchlight, a pioneering leader in DNA manufacturing technologies, has been named the 2025 FOYA Category Winner for Innovation in the International Society for Pharmaceutical Engineering (ISPE) Facility of the Year…
Read More
